caa a22 4500 475833198 CHVBK 20180406123846.0 cr unu---uuuuu 170329e20000201xx s 000 0 eng 10.1023/A:1007858100639 doi (NATIONALLICENCE)springer-10.1023/A:1007858100639 Jespersen Christian Department of Cardiovascular Medicine Y, Bispebjerg Hospital, Copenhagen, Denmark aut Erratum: Verapamil in Acute Myocardial Infarction. The Rationales of the VAMI and DAVIT III Trials [Elektronische Daten] [Christian Jespersen] Verapamil is well tolerated in patients with stable and unstable angina pectoris, as well as in patients with threatened infarction. No data exist documenting verapamil to be inferior to beta-blockers in these stages of coronary heart diseases. In the prethrombolytic era i.v. intervention with verapamil did not add any benefit in the early phase of AMI. However, a retrospective analysis suggests the hypothesis that i.v. verapamil given in combination with thrombolysis may improve the prognosis, and an ongoing study (VAMI trial) examines this hypothesis. When given in the late in-hospital phase of AMI to patients without heart failure verapamil significantly reduces mortality and morbidity. When given in the late in-hospital phase to patients with heart failure verapamil did not cause the course or prognosis to deteriorate and might even improve it in patients with residual ischaemia, especially when given in combination with an ACE-inhibitors. A planned study (DAVIT III study) has to confirm these preliminary data. Kluwer Academic Publishers, 2000 verapamil nationallicence thrombolysis nationallicence heart failure nationallicence acute myocardial infarction nationallicence Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/1(2000-02-01), 97-106 0920-3206 14:1<97 2000 14 10557 https://doi.org/10.1023/A:1007858100639 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007858100639 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Jespersen Christian Department of Cardiovascular Medicine Y, Bispebjerg Hospital, Copenhagen, Denmark aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/1(2000-02-01), 97-106 0920-3206 14:1<97 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer